We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

DNA Health Monitoring Campaign Launched

By LabMedica International staff writers
Posted on 11 Feb 2014
Print article
A DNA health test aims to assist in prevention of diseases associated with DNA damage and poor DNA repair.

The Berkeley-based startup, Exogen Biotechnology (CA, USA), has launched a unique citizen science campaign on Indiegogo, a global “crowd funding” website (San Francisco, CA, USA). The campaign is based on a laboratory test, which measures DNA breaks, the most lethal type of DNA damage and a potentially key indicator for overall health conditions. Launched on January 25, 2013, the project raised USD 20,000 in “crowd funding” within its first three days.

The technology measures physical breaks in the DNA of cells, which commonly result from an individual's lifestyle, environmental toxins, or personal genetics. The startup from the Lawrence Berkeley National Laboratory envisions that its DNA health monitoring technology will one day be as commonplace as a cholesterol test. The DNA health test aims to assist in prevention of diseases associated with DNA damage and poor DNA repair.

Exogen is allowing the public to assist in funding its large-scale citizen scientist project as well as gain access to the technology that is not yet available to the public. Supporters receive a kit that allows funders to safely collect three blood samples via sterile finger pricks. Blood samples are then mailed to Exogen’s proprietary research lab and analyzed either as a one-time event or on a regular basis throughout the year. The blood is processed for DNA damage and the results are made available back to the funder, securely and privately via a protected web application.

The core team behind the project is comprised of Dr. Sylvain Costes and Dr. Jonathan Tang, who are experts in understanding the link between ionizing radiation, DNA damage, and cancer induction. They developed this leading-edge technology over the past 10 years at the Lawrence Berkeley National Laboratory.

Dr. Tang commented, “Breaks in our DNA occur frequently, and our bodies repair them every day. However, as we age, the efficiency of how our bodies repair DNA breaks seems to weaken. This decline in repair efficiency can lead to accumulation of unrepaired DNA or misrepaired DNA, which may result in unpredictable and potentially lethal genetic mutations. Exogen hopes that monitoring DNA for breaks will allow individuals to assess the impact of various lifestyles and environments on their overall health and aging.”

Related Links:

Exogen Biotechnology


Flocked Swab
HydraFlock and PurFlock Ultra
Gold Supplier
PCR Microplate
SAPPHIRE MICROPLATE
New
Semi-Automatic Coagulation Analyzer
Clot 2B
New
Cardiac Test
ImmunTech Cardiac Triple Test

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Industry

view channel
Image: The Coris acquisition provides Avacta with a broad, professional-use rapid test product portfolio (Photo courtesy of Coris Bioconcept)

Avacta Expands Diagnostics Portfolio with Acquisition of Rapid Test Maker Coris Bioconcept

Avacta Group plc (London, UK), a life sciences company developing oncology drugs and diagnostics, has acquired Coris Bioconcept SRL (Gembloux, Belgium) for an upfront cash consideration of GBP 7.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.